Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy.
Wang Y-J. et al, (2025), Sci Transl Med, 17
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.
Saberi S. et al, (2025), JACC Heart Fail, 13
An ALPK3 truncation variant causing autosomal dominant hypertrophic cardiomyopathy is partially rescued by mavacamten.
Leinhos L. et al, (2025), Sci Rep, 15
Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy.
Tadros R. et al, (2025), Nat Genet, 57, 530 - 538
Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings.
Zheng SL. et al, (2025), Nat Genet
Multiparametric cardiovascular magnetic resonance evaluation of myocardial perfusion, oxygenation, and energetics in hypertrophic cardiomyopathy following cardiac myosin inhibitor therapy.
Finnigan LEM. et al, (2025), Eur Heart J Cardiovasc Imaging, 26
Myocardial disarray and fibrosis across hypertrophic cardiomyopathy stages associate with ECG markers of arrhythmic risk.
Ashkir Z. et al, (2025), Eur Heart J Cardiovasc Imaging, 26, 218 - 228
Etiology and Phenotypes of Cardiomyopathy in Southern Africa: The IMHOTEP Multicenter Pilot Study.
Kraus SM. et al, (2024), JACC Adv, 3
Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy.
Tahir UA. et al, (2024), Circ Heart Fail, 17
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial.
Coats CJ. et al, (2024), Eur Heart J, 45, 4464 - 4478
Genetic therapies for cardiomyopathy: survey of attitudes of the patient community for the CureHeart project.
Ormondroyd E. et al, (2024), Eur J Hum Genet, 32, 1045 - 1052
A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome.
Ni M. et al, (2024), JAMA, 332, 204 - 213
Mechanisms of ischaemia-induced arrhythmias in hypertrophic cardiomyopathy: a large-scale computational study.
Coleman JA. et al, (2024), Cardiovasc Res, 120, 914 - 926
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Coats CJ. et al, (2024), Journal of the American Heart Association
Flow inefficiencies in non-obstructive HCM revealed by kinetic energy and hemodynamic forces on 4D-flow CMR.
Pola K. et al, (2024), Eur Heart J Imaging Methods Pract, 2
Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study.
Siontis KC. et al, (2024), Eur Heart J Digit Health, 5, 416 - 426
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Maron MS. et al, (2024), N Engl J Med, 390, 1849 - 1861